Get the Stockscreener App
9.87
0.00%
0.00
Drugs Made In America Acquisition Ii Corp stock is traded at $9.87, with a volume of 23,977.
It is up +0.00% in the last 24 hours and up +0.00% over the past month.
Drugs Made In America Acquisition II Corp is a blank check Company.
See More
Previous Close:
$9.87
Open:
$9.88
24h Volume:
23,977
Relative Volume:
0.95
Market Cap:
$647.23M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.10%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$9.87
$9.89
1-Week Range:
$9.87
$9.89
52-Week Range:
$9.87
$9.89
Drugs Made In America Acquisition Ii Corp Stock (DMII) Company Profile
Name
Drugs Made In America Acquisition Ii Corp
Sector
Industry
Phone
954-870-3104
Address
1 EAST BROWARD BOULEVARD, FORT LAUDERDALE
Compare DMII with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DMII
Drugs Made In America Acquisition Ii Corp
|
9.87 | 647.23M | 0 | 0 | 0 | 0.00 |
|
XXI
Twenty One Capital Inc
|
11.50 | 4.04B | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.19 | 2.39B | 3.13B | -174.20M | -111.20M | -0.6937 |
|
CCCX
Churchill Capital Corp X
|
14.91 | 764.09M | 0 | 0 | 0 | 0.00 |
|
BCSS
Bain Capital Gss Investment Corp
|
10.12 | 589.84M | 0 | 0 | 0 | 0.00 |
Drugs Made In America Acquisition Ii Corp Stock (DMII) Latest News
Aug Movers: Is Drugs Made In America Acquisition Corp stock a top momentum playWeekly Volume Report & Free Technical Pattern Based Buy Signals - moha.gov.vn
What analysts say about Drugs Made In America Acquisition Corp stockDividend Yield Trends & Exceptional Profit Portfolio - earlytimes.in
Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) is largely controlled by institutional shareholders who own 79% of the company - Yahoo Finance
Hims & Hers acquires Livewell in Canada in anticipation of generic Ozempic - The Globe and Mail
Drugs Made In America Appoints New CFO - MSN
Drugs Made In America Acquisition II Corp. Announces the Separate Trading of its Ordinary Shares and Rights Commencing December 3, 2025 - Markets Financial Content
Layoff Tracker: Adare Shuts Down Philadelphia Plant, Leaving 137 Jobless - BioSpace
Prescription Drug Costs - Britannica
BMK Pharma To Open $50M U.S. HQ and Pharmaceutical Facility in Allen - Dallas Innovates
CVS Pharmacy Completes Acquisition of Rite Aid Assets - Progressive Grocer
FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - statnews.com
Trump Wants to Overhaul Drug Sales. A Company Tied to His Son Stands to Benefit | World News - Hindustan Times
Canadian tech helped U.S. strike alleged Venezuelan drug boats: report - CBC
Drugs Made In America Acquisition II Corp. completes $500 million IPO and private placement - Investing.com
Drugs Made In America Acquisition II Corp. closes $500 million IPO - Investing.com
Drugs Made In America $500M In IPO Marks 2025’s Biggest SPAC Debut - USA Herald
Celltrion buys Eli Lilly’s New Jersey plant for $330 million - The Korea Economic Daily Global Edition
Kenvue, the Company Behind Tylenol, Tries to Navigate Its Latest Crisis - The New York Times
$10B Domestic Drug Production Deal: PharmAGRI and Tesla to Deploy 10,000 Robots for US Prescription Drugs - Stock Titan
Bright Green Corporation Merges with PharmAGRI Capital Partners; Lynn Stockwell Appointed CEO and Chairwoman - GlobeNewswire
U.S. Drugmakers Warn White House of Chaos as Trump Weighs Curbs on China - The New York Times
Drugs Made In America Acquisition Corp. (NASDAQ:DMAA) is definitely on the radar of institutional investors who own 38% of the company - Yahoo Finance
CSL's Venofer finally faces generic competition as FDA clears copycats from Viatris, Sandoz and Amphastar - Fierce Pharma
UPDATED: Most expensive drugs in the US in 2025 - Fierce Pharma
Updated: AstraZeneca reports revenue growth, pipeline tweaks as it ponders price cuts, direct-to-patient sales - Endpoints News
Pharmalittle: We're reading about Sarepta resisting FDA over Elevidys, agency naming top drug regulator, and more - statnews.com
US FDA approves Regeneron's blood cancer therapy - Reuters
US pharma bets big on China to snap up potential blockbuster drugs - Reuters
Markets News, May 12, 2025: Stocks Surge After US, China Agree to Slash Tariffs; Dow Jumps Nearly 1,200 Points as Amazon, Apple, Nike Soar - Investopedia
The top 20 pharma companies by 2024 revenue - Fierce Pharma
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - qz.com
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - GlobeNewswire
The top 10 drugs losing US exclusivity in 2025 - Fierce Pharma
7 Best Weight Loss Drug Stocks to Buy in 2025 - US News Money
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Announces Advisory Team - GlobeNewswire
Popular cannabis brand declares Chapter 11 bankruptcy - thestreet.com
Hims & Hers Acquires US-based Peptide Facility - Hims Investor Relations
SPAC Alert: Key Trading Change Coming for Drugs Made In America UnitsWhat Investors Should Track - Stock Titan
U.S. investors, Big Pharma race to find new medicines in China - CNBC
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing - ProPublica
Bain throws down $3.3B to acquire Japan's Mitsubishi Tanabe Pharma - Fierce Pharma
Merck touts 20 new ‘blockbuster’ drugs in development with $50 billion potential - Fortune
IPO NewsUS IPO Weekly Recap: Active January closes out with several sizable IPOs - renaissancecapital.com
Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq - Nasdaq
Drugs Made In America SPAC Nets $200M To Buy Pharma Biz - Law360
Top 10 most anticipated drug launches of 2025 - Fierce Pharma
Danone’s yogurt sales surge among US consumers using GLP-1 drugs - Food Dive
UnitedHealth Charged Cancer Patients 5000%, Bombshell FTC Report Claims - Newsweek
Drugs Made In America Acquisition Ii Corp Stock (DMII) Financials Data
There is no financial data for Drugs Made In America Acquisition Ii Corp (DMII). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.20%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):